These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 23321647)

  • 1. Losartan added to β-blockade therapy for aortic root dilation in Marfan syndrome: a randomized, open-label pilot study.
    Chiu HH; Wu MH; Wang JK; Lu CW; Chiu SN; Chen CA; Lin MT; Hu FC
    Mayo Clin Proc; 2013 Mar; 88(3):271-6. PubMed ID: 23321647
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Retrospective analysis of the effect of angiotensin II receptor blocker versus β-blocker on aortic root growth in paediatric patients with Marfan syndrome.
    Mueller GC; Stierle L; Stark V; Steiner K; von Kodolitsch Y; Weil J; Mir TS
    Heart; 2014 Feb; 100(3):214-8. PubMed ID: 24270746
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized, double blind pilot study to assess the effects of losartan vs. atenolol on the biophysical properties of the aorta in patients with Marfan and Loeys-Dietz syndromes.
    Sandor GG; Alghamdi MH; Raffin LA; Potts MT; Williams LD; Potts JE; Kiess M; van Breemen C
    Int J Cardiol; 2015 Jan; 179():470-5. PubMed ID: 25465809
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of losartan vs. atenolol for the prevention of aortic dilation in Marfan syndrome: a randomized clinical trial.
    Forteza A; Evangelista A; Sánchez V; Teixidó-Turà G; Sanz P; Gutiérrez L; Gracia T; Centeno J; Rodríguez-Palomares J; Rufilanchas JJ; Cortina J; Ferreira-González I; García-Dorado D
    Eur Heart J; 2016 Mar; 37(12):978-85. PubMed ID: 26518245
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Losartan Versus Atenolol for Prevention of Aortic Dilation in Patients With Marfan Syndrome.
    Teixido-Tura G; Forteza A; Rodríguez-Palomares J; González Mirelis J; Gutiérrez L; Sánchez V; Ibáñez B; García-Dorado D; Evangelista A
    J Am Coll Cardiol; 2018 Oct; 72(14):1613-1618. PubMed ID: 30261963
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rationale and design of a trial evaluating the effects of losartan vs. nebivolol vs. the association of both on the progression of aortic root dilation in Marfan syndrome with FBN1 gene mutations.
    Gambarin FI; Favalli V; Serio A; Regazzi M; Pasotti M; Klersy C; Dore R; Mannarino S; Viganò M; Odero A; Amato S; Tavazzi L; Arbustini E
    J Cardiovasc Med (Hagerstown); 2009 Apr; 10(4):354-62. PubMed ID: 19430350
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pravastatin reduces Marfan aortic dilation.
    McLoughlin D; McGuinness J; Byrne J; Terzo E; Huuskonen V; McAllister H; Black A; Kearney S; Kay E; Hill AD; Dietz HC; Redmond JM
    Circulation; 2011 Sep; 124(11 Suppl):S168-73. PubMed ID: 21911808
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Losartan or Atenolol on Children and Young Adults With Bicuspid Aortic Valve and Dilated Aorta.
    Flyer JN; Sleeper LA; Colan SD; Singh MN; Lacro RV
    Am J Cardiol; 2021 Apr; 144():111-117. PubMed ID: 33383013
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Losartan reduces aortic dilatation rate in adults with Marfan syndrome: a randomized controlled trial.
    Groenink M; den Hartog AW; Franken R; Radonic T; de Waard V; Timmermans J; Scholte AJ; van den Berg MP; Spijkerboer AM; Marquering HA; Zwinderman AH; Mulder BJ
    Eur Heart J; 2013 Dec; 34(45):3491-500. PubMed ID: 23999449
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Ghent Marfan Trial--a randomized, double-blind placebo controlled trial with losartan in Marfan patients treated with β-blockers.
    Möberg K; De Nobele S; Devos D; Goetghebeur E; Segers P; Trachet B; Vervaet C; Renard M; Coucke P; Loeys B; De Paepe A; De Backer J
    Int J Cardiol; 2012 Jun; 157(3):354-8. PubMed ID: 21239069
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Marfan Sartan: a randomized, double-blind, placebo-controlled trial.
    Milleron O; Arnoult F; Ropers J; Aegerter P; Detaint D; Delorme G; Attias D; Tubach F; Dupuis-Girod S; Plauchu H; Barthelet M; Sassolas F; Pangaud N; Naudion S; Thomas-Chabaneix J; Dulac Y; Edouard T; Wolf JE; Faivre L; Odent S; Basquin A; Habib G; Collignon P; Boileau C; Jondeau G
    Eur Heart J; 2015 Aug; 36(32):2160-6. PubMed ID: 25935877
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Study of the efficacy and safety of losartan versus atenolol for aortic dilation in patients with Marfan syndrome].
    Forteza A; Evangelista A; Sánchez V; Teixidó G; García D; Sanz P; Gutiérrez L; Centeno J; Rodríguez-Palomares J; Cortina J; García-Dorado D
    Rev Esp Cardiol; 2011 Jun; 64(6):492-8. PubMed ID: 21561700
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effects of losartan versus beta-blockers on cardiovascular protection in marfan syndrome: A systematic review and meta-analysis.
    Kang YN; Chi SC; Wu MH; Chiu HH
    J Formos Med Assoc; 2020 Jan; 119(1 Pt 1):182-190. PubMed ID: 31003918
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictors of Rapid Aortic Root Dilation and Referral for Aortic Surgery in Marfan Syndrome.
    Hoskoppal A; Menon S; Trachtenberg F; Burns KM; De Backer J; Gelb BD; Gleason M; James J; Lai WW; Liou A; Mahony L; Olson AK; Pyeritz RE; Sharkey AM; Stylianou M; Wechsler SB; Young L; Levine JC; Tierney ESS; Lacro RV; Bradley TJ;
    Pediatr Cardiol; 2018 Oct; 39(7):1453-1461. PubMed ID: 29948025
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Distinct effects of losartan and atenolol on vascular stiffness in Marfan syndrome.
    Bhatt AB; Buck JS; Zuflacht JP; Milian J; Kadivar S; Gauvreau K; Singh MN; Creager MA
    Vasc Med; 2015 Aug; 20(4):317-25. PubMed ID: 25795452
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characteristics of children and young adults with Marfan syndrome and aortic root dilation in a randomized trial comparing atenolol and losartan therapy.
    Lacro RV; Guey LT; Dietz HC; Pearson GD; Yetman AT; Gelb BD; Loeys BL; Benson DW; Bradley TJ; De Backer J; Forbus GA; Klein GL; Lai WW; Levine JC; Lewin MB; Markham LW; Paridon SM; Pierpont ME; Radojewski E; Selamet Tierney ES; Sharkey AM; Wechsler SB; Mahony L;
    Am Heart J; 2013 May; 165(5):828-835.e3. PubMed ID: 23622922
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rationale and design of a randomized clinical trial of beta-blocker therapy (atenolol) versus angiotensin II receptor blocker therapy (losartan) in individuals with Marfan syndrome.
    Lacro RV; Dietz HC; Wruck LM; Bradley TJ; Colan SD; Devereux RB; Klein GL; Li JS; Minich LL; Paridon SM; Pearson GD; Printz BF; Pyeritz RE; Radojewski E; Roman MJ; Saul JP; Stylianou MP; Mahony L;
    Am Heart J; 2007 Oct; 154(4):624-31. PubMed ID: 17892982
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Placebo effect and efficacy of nebivolol in patients with hypertension not controlled with lisinopril or losartan: a phase IV, randomized, placebo-controlled trial.
    Weiss RJ; Stapff M; Lin Y
    Am J Cardiovasc Drugs; 2013 Apr; 13(2):129-40. PubMed ID: 23519546
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Usefulness of enalapril versus propranolol or atenolol for prevention of aortic dilation in patients with the Marfan syndrome.
    Yetman AT; Bornemeier RA; McCrindle BW
    Am J Cardiol; 2005 May; 95(9):1125-7. PubMed ID: 15842990
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Meta-analysis Examining the Usefulness of Angiotensin Receptor blockers for the Prevention of Aortic Root Dilation in Patients With the Marfan Syndrome.
    Al-Abcha A; Saleh Y; Mujer M; Boumegouas M; Herzallah K; Charles L; Elkhatib L; Abdelkarim O; Kehdi M; Abela GS
    Am J Cardiol; 2020 Aug; 128():101-106. PubMed ID: 32650901
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.